China Pharma Holdings closes $5M direct offering at $2 per share

China Pharma Holdings, Inc. (NYSE American: CPHI) announced the closing of a registered direct offering of 2,500,000 shares of common stock at $2.00 per share, generating $5 million in gross proceeds before placement agent fees and other expenses.

The offering closed on July 23, 2026. The company said it intends to use the net proceeds for working capital and general corporate purposes.

FT Global Capital, Inc. served as the exclusive placement agent for the offering.

The offering was made under the company's shelf registration statement on Form S-3, initially filed with the U.S. Securities and Exchange Commission on January 12, 2024, and declared effective on February 14, 2024.

China Pharma Holdings is a specialty pharmaceutical company based in Haikou, China, focused on cardiovascular, central nervous system, infectious, and digestive disease treatments.

You May Also Be Interested In

• Singularity Future Technology closes $5M registered direct offering
• Gossamer Bio raises up to $250M in private placement for PAH drug
• ESS Tech closes $3.2M stock offering at $0.50 per share